文献速递胸部肿瘤

肺癌MET外显子14突变对八种MET酪氨酸激酶抑制剂的体外敏感性与耐药性

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
PubMed 文献 · J Thorac Oncol · 2019-07-03

本研究通过逆转录病毒基因转移构建表达MET外显子14突变的Ba/F3细胞,用比色法测定其对八种MET酪氨酸激酶抑制剂(TKI)的敏感性,并利用N-乙基-N-亚硝基脲诱变生成耐药克隆、寻找二次MET突变。结果显示这些细胞除对tivantinib外对所有MET-TKI敏感;I型TKI耐药突变常见于D1228和Y1230,II型常见于L1195和F1200,且I型与II型抑制剂对相应耐药突变存在互补活性。

要点

  • MET外显子14突变细胞除tivantinib外对多种MET-TKI敏感。
  • I型TKI耐药突变常见D1228、Y1230,II型常见L1195、F1200。
  • I型与II型MET-TKI对彼此耐药突变具有互补活性。

核心结论

  • MET-TKI可抑制携带MET外显子14突变的细胞生长,且I型与II型抑制剂对耐药突变存在互补活性。

研究设计与样本

  • 研究通过逆转录病毒基因转移构建表达MET外显子14突变的Ba/F3细胞,并用比色法测定其对八种MET-TKI的敏感性。
  • 利用N-乙基-N-亚硝基脲诱变生成耐药克隆,搜索二次MET突变并检测耐药细胞对不同TKI的敏感性。

主要发现

  • 转染MET突变的Ba/F3细胞在无白细胞介素-3条件下生长,提示其致癌活性。
  • 这些细胞除对tivantinib外对所有MET-TKI敏感。
  • 鉴定出多种二次突变,I型TKI(结合MET活性构象)耐药突变常见位点为D1228和Y1230。
  • II型TKI(结合MET非活性构象)耐药突变常见位点为L1195和F1200。
  • 总体上,对I型TKI耐药的突变对II型TKI敏感,反之亦然。

临床怎么用

  • 提示对MET外显子14突变肺癌患者,I型与II型MET-TKI可能根据耐药突变位点互补使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MNNG HOS transforming gene (MET) exon 14 mutations in lung cancer, including exon 14 skipping and point mutations, have been attracting the attention of thoracic oncologists as new therapeutic targets. Tumors with these mutations almost always acquire resistance, which also occurs in other oncogene-addicted lung cancers. However, the resistance mechanisms and treatment strategies are not fully understood. METHODS: We generated Ba/F3 cells expressing MET exon 14 mutations by retroviral gene transfer. The sensitivities of these cells to eight MET-tyrosine kinase inhibitors (TKIs) were determined using a colorimetric assay. In addition, using N-ethyl-N-nitrosourea mutagenesis, we generated resistant clones, searched for secondary MET mutations, and then examined the sensitivities of these resistant cells to different TKIs. RESULTS: Ba/F3 cells transfected with MET mutations grew in the absence of interleukin-3, indicating their oncogenic activity. These cells were sensitive to all MET-TKIs except tivantinib. We identified a variety of secondary mutations. D1228 and Y1230 were common sites for resistance mutations for type I TKIs, which bind the active form of MET, whereas L1195 and F1200 were common sites for type II TKIs, which bind the inactive form. In general, resistance mutations against type I were sensitive to type II, and vice versa. CONCLUSIONS: MET-TKIs inhibited the growth of cells with MET exon 14 mutations. We also identified mutation sites specific for TKI types as resistance mechanisms and complementary activities between type I and type II inhibitors against those mutations. These finding should provide relevant clinical implication for treating patients with lung cancer harboring MET exon 14 mutations.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Fujino T, Kobayashi Y, Suda K, et al. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. J Thorac Oncol. 2019. PMID: 31279006. doi:10.1016/j.jtho.2019.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。